ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0371

Assessing Methotrexate Adherence in JIA Using Electronic Health Record-Linked Pharmacy Dispensing Data

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-11:00AM: Abstract Number: 0162

Assessing Reproductive Health Counseling and Provider Attitudes in Rheumatology Post Roe v. Wade in Houston, Texas

(0155–0175) Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 0043

Assessing the Ability of Human Dental Pulp Stem Cells to Modulate the Macrophages Phenotype

(0040–0064) Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0342

Assessing the Known-group Validity of the IDEOM MSK-Q Using Data from the National Psoriasis Foundation Annual Survey

(0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 0326

Assessment of Depression in Ankylosing Spondylitis Using Center for Epidemiologic Studies Depression Scale

(0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 0509

Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

9:00AM-11:00AM: Abstract Number: 0508

Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

9:00AM-11:00AM: Abstract Number: 0331

Assessment of Patient Adherence to “Sick Day Rules”: A Cross-sectional Study of Rheumatology Outpatients Prescribed Immunosuppressive Medications

(0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 0661

Assessment of Systemic Sclerosis-Associated Myocarditis: A Single Center Case Series Study

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0188

Association Between Area Deprivation Index and Organ Damage Accumulation in a Statewide Incident Lupus Cohort

(0176–0195) Healthcare Disparities in Rheumatology Poster I: Lupus

9:00AM-11:00AM: Abstract Number: 0438

Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review

(0423–0459) RA – Treatments Poster I

9:00AM-11:00AM: Abstract Number: 0416

Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0653

Association Between Systemic Sclerosis and Increased Risk of Ischemic Stroke: A Meta-Analysis

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0334

Association of a Self-Report Screening Tool for Sarcopenia (SARC-F) with Functional Status Outcomes in Systemic Lupus Erythematosus

(0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 0414

Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

«Previous Page
1
…
3
4
5
6
7
…
59
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].